Voyager Therapeutics Inc. (NASDAQ:VYGR)’s share price rose 5.9% on Friday . The stock traded as high as $13.92 and last traded at $13.41, with a volume of 54,282 shares changing hands. The stock had previously closed at $12.66.

VYGR has been the topic of several analyst reports. Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, April 8th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Saturday, April 30th. Wells Fargo & Co. assumed coverage on Voyager Therapeutics in a research report on Friday, May 20th. They set an “outperform” rating on the stock. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $30.25.

The stock’s 50 day moving average price is $12.70 and its 200 day moving average price is $11.82. The stock’s market cap is $370.21 million.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, May 12th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.67. On average, equities research analysts expect that Voyager Therapeutics Inc. will post ($1.46) earnings per share for the current year.

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.